Dr Fernando Garces

Dr Garces boasts a distinguished career. Holding a bachelor's degree in microbiology from the Catholic University in Porto, Portugal, he pursued international recognition during his PhD fellowship at the University of Barcelona, specialising in structural biology and biochemistry. Subsequent roles at the Institute of Cancer Research and The Scripps Research Institute solidified his expertise in protein design and vaccine development, leading to the 2015 Scripps CHAVI-ID Young Investigator Award.

Joining Amgen in 2016, Fernando pioneered a protein engineering team and contributed to industry-leading workflows for multi-specific antibodies. His mentorship produced numerous publications. In 2021, he assumed the role of Director in Protein Therapeutics at Gilead, driving biologics to prominence. With approximately 35 peer-reviewed publications and over 20 patents, Fernando's contributions to biotechnology and innovation are profound.